FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

Feb 3, 2025, 12:18 PM
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Read more.
Categories :
  • Public Health Alert
Load more comments
avatar
Login to be able to comment

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

Last Updated: Feb 3, 2025

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Read more.

Login to be able to comment

Leave a comment

ProAssurance
AmeriTrust Connect